Gamze Bilgili¹, Merve Alpay², Deniz Ceylanli³, Sevgi Gençosman³, Çağri Gültekin⁴, Ahmet Özer Şehirli⁵ and Serkan Sayiner³*

¹Faculty of Veterinary Medicine, Near East University, 99138 Nicosia, North Cyprus, Mersin 10, Turkey
²Department of Biochemistry, Faculty of Medicine, Duzce University, 81620 Düzce, Turkey
³Department of Biochemistry, Faculty of Veterinary Medicine, Near East University, 99138 Nicosia, North Cyprus, Mersin 10, Turkey
⁴Department of Surgery, Faculty of Veterinary Medicine, Near East University, 99138 Nicosia, North Cyprus, Mersin 10, Turkey
⁵Department of Pharmacology, Faculty of Dentistry, Near East University, 99138 Nicosia, North Cyprus, Mersin 10, Turkey

*Corresponding Author: Serkan Sayiner, Associate Professor, Department of Biochemistry, Faculty of Veterinary Medicine, Near East University, 99138 Nicosia, North Cyprus, Mersin 10, Turkey.

Received: December 20, 2021; Published: January 31, 2022

Abstract

Tumour markers, also known as biomarkers, might be proteins, conjugated proteins, peptides, or carbohydrates. Tumour markers are substances that are created by cancer cells or by the organism in response to cancer. According to the dictionary of cancer terms published online by the National Cancer Institute (NCI), a biomarker is “A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease.” These molecules are present in the blood, urine, tissues, and body fluids (cerebrospinal fluid, synovial fluid, pancreatic fluid, Etc.). However, blood levels are primarily examined. Tumour markers are never utilized to make a cancer diagnosis. Mammography, ultrasound, computed tomography, magnetic resonance imaging scans, and tumour marker assays are used to aid in the diagnosis, monitor the progression of the disease (prognosis), detect recurrence, and aid in the application of treatment. While these procedures are beneficial for staging cancer, a biopsy is usually required to confirm the diagnosis. Considering tumour markers is an exciting field for both veterinary oncology and human medicine, the purpose of this study is to provide current and relevant information for the future use of tumour markers for the diagnosis and prognosis of increasing cancer cases in animals by reviewing previous studies.

Keywords: Cassava Pellets; Goats; Digestibility; Plasma; Milk

References

1. Amorim RL., et al. "Serum and urinary measurements of prostatic acid phosphatase (PAP) and prostatic specific antigen (PSA) in dogs". Arquivo Brasileiro de Medicina Veterinária e Zootecnia3 (2004): 320-324.
2. Bolliger AP., et al. "Detection of parathyroid hormone-related protein in cats with humoral hypercalcemia of malignancy". Veterinary Clinical Pathology1 (2002): 3-8.
3. Brömel C., et al. "Serum Inhibin Concentration in Dogs with Adrenal Gland Disease and in Healthy Dogs". Journal of Veterinary Internal Medicine1 (2013): 76-82.
4. Brunetti B., et al. "p53, ER, and Ki67 Expression in Canine Mammary Carcinomas and Correlation with Pathological Variables and Prognosis". Veterinary Pathology2 (2021): 325-331.
5. Cadile CD., et al. "Telomerase activity as a marker for malignancy in feline tissues". American Journal of Veterinary Research 10 (2001): 1578-1581.
6. Campos LC., et al. "CA15.3, CEA and LDH in Dogs with Malignant Mammary Tumors". Journal of Veterinary Internal Medicine6 (2012): 1383-1388.
7. Ebisawa M., et al. "Significance of caveolin-1 and matrix metalloproteinase 14 gene expression in canine mammary tumours". The Veterinary Journal2 (2015): 191-196.
8. von Euler HP., et al. "A non-radiometric method for measuring serum thymidine kinase activity in malignant lymphoma in dogs". Research in Veterinary Science1 (2006): 17-24.
9. Fan Y., et al. "Combined detection of CA15-3, CEA, and SF in serum and tissue of canine mammary gland tumor patients". Scientific Reports1 (2021): 6651.
10. Feldman EC., et al. "Pretreatment clinical and laboratory findings in dogs with primary hyperparathyroidism: 210 Cases (1987-2004)". Journal of the American Veterinary Medical Association 5 (2005): 756-761.
11. Golchin-Rad K., et al. "Changes in specific serum biomarkers during the induction of prostatic hyperplasia in dogs". BMC Veterinary Research1 (2019): 440.
12. Granger N., et al. "Plasma Pro-opiomelanocortin, Pro-adrenocorticotropin Hormone, and Pituitary Adenoma Size in Dogs with Cushing’s Disease". Journal of Veterinary Internal Medicine1 (2005): 23-28.
13. Graves TK., et al. "Diagnostic tests for feline hyperthyroidism". Veterinary Clinics of North America - Small Animal Practice 3 (1994).
14. Hahn KA., et al. "Serum alpha 1-acid glycoprotein concentrations before and after relapse in dogs with lymphoma treated with doxorubicin.". Journal of the American Veterinary Medical Association7 (1999): 1023-5.
15. Henson KL., et al. "Regression of subcutaneous lymphoma following removal of an ovarian granulosatheca cell tumor in a horse". Journal of the American Veterinary Medical Association9 (1998): 1419-1422.
16. Hill KE., et al. "Secretion of sex hormones in dogs with adrenal dysfunction". Journal of the American Veterinary Medical Association4 (2005): 556-561.
17. Hirschberger J., et al. "Fibronectin concentrations in pleural and abdominal effusions in dogs and cats". Journal of Veterinary Internal Medicine5 (1996): 321-325.
18. Hofer J., et al. "Detection of tumour necrosis factor-alpha in dogs with lymphoma*". Veterinary and Comparative Oncology4 (2011): 290-295.
19. Hoque S., et al. "Endocrinological changes before and after removal of the granulosa theca cell tumor (GTCT) affected ovary in 6 mares". Journal of Veterinary Medical Science8 (2003): 887-891.
20. Illera JC., et al. "Steroids and receptors in canine mammary cancer". Steroids 71.7 (2006): 541-548.
21. Karayannopoulou M., et al. "Serum alkaline phosphatase isoenzyme activities in canine malignant mammary neoplasms with and without osseous transformation". Veterinary Clinical Pathology3 (2006): 287-290.
22. Key TJA. et al. "Hormones and cancer in humans". Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis1-2 (1995): 59-67.
23. Kitao S., et al. "Alpha-Fetoprotein in Serum and Tumor Tissues in Dogs with Hepatocellular Carcinoma". Journal of Veterinary Diagnostic Investigation3 (2006): 291-295.
24. van der Kolk JH., et al. "Laboratory diagnosis of equine pituitary pars intermedia adenoma.". Domestic animal endocrinology1 (1995): 35-9.
25. Lautzenhiser SJ., et al. "Unusual IgM-secreting multiple myeloma in a dog". Journal of the American Veterinary Medical Association5 (2003): 645-648+636.
26. Marconato L., et al. "Serum lactate dehydrogenase activity in canine malignancies". Veterinary and Comparative Oncology 4 (2009): 236-243.
27. Medan MS., et al. "Plasma concentrations of Ir-inhibin, Inhibin A, Inhibin pro-αC, FSH, and estradiol-17β during estrous cycle in mares and their relationship with follicular growth". Endocrine1 (2004): 7-14.
28. Morris J and Dobson J. “Small Animal Oncology”.
29. Nagpal M., et al. "Tumor markers: A diagnostic tool". National Journal of Maxillofacial Surgery1 (2016): 17.
30. Newkirk KM., et al. "Neoplasia and Tumor Biology". In: Pathologic Basis of Veterinary Disease Expert Consult. 2017:286-321.e1.
31. Paltrinieri S., et al. "Sialic Acid and Sialyltransferase Activity in Serum and Tissues of Dogs With Mammary Tumors". Veterinary Pathology4 (2012): 669-681.
32. Peterson ME., et al. "Radioiodine treatment of 524 cats with hyperthyroidism". Journal of the American Veterinary Medical Association11 (1995): 1422-1428.
33. Peterson ME., et al. "Measurement of serum concentrations of free thyroxine, total thyroxine, and total triiodothyronine in cats with hyperthyroidism and cats with nonthyroidal disease". Journal of the American Veterinary Medical Association4 (2001): 529-536.
34. Platt SR., et al. "Vascular endothelial growth factor expression in canine intracranial meningiomas and association with patient survival". Journal of Veterinary Internal Medicine3 (2006): 663-668.
35. Renaudin CD., et al. "Equine granulosa cell tumours among other ovarian conditions: Diagnostic challenges". Equine Veterinary Journal1 (2021): 60-70.
36. Sharma S., et al. "Tumor markers in clinical practice: General principles and guidelines". Indian Journal of Medical and Paediatric Oncology 01 (2009): 1-8.
37. Sokoll LJ., et al. "Tumor markers". In: Contemporary Practice in Clinical Chemistry. Elsevier; 2020:779-793.
38. Szweda M., et al. "Cyclooxygenase-2 as a biomarker with diagnostic, therapeutic, prognostic, and predictive relevance in small animal oncology". Journal of Veterinary Research 1 (2020): 151-160.
39. Tecles F., et al. "Preliminary Studies of Serum Acute-Phase Protein Concentrations in Hematologic and Neoplastic Diseases of the Dog". Journal of Veterinary Internal Medicine 19.6 (2005): 865-870.
40. Zhou L., et al. "Serum tumor markers for detection of hepatocellular carcinoma". World Journal of Gastroenterology 8 (2006): 1175-1181.

Citation

Citation: Serkan Sayiner., et al. “Current Knowledge on Tumour Markers in Veterinary Oncology". Acta Scientific Veterinary Sciences 4.2 (2022): 37-45.

Copyright

Copyright: © 2022 Serkan Sayiner., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.